Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUDIBLE-S: SENS-401 in Sudden Sensorineural Hearing Loss
NCT03603314Phase 3Completed
- Sponsor
- Sensorion
- Start
- Feb 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of arazasetron besylate in sudden sensorineural hearing loss (SSHL) (3 arms), sponsored by Sensorion. Primary endpoint: Change in Pure Tone Audiometry PTA (dB) From Baseline to the End of Treatment Visit at 28 days. Started Feb 2019; status: completed.
02
Drugs
arazasetron besylate
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT03603314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603314.